BioGend Therapeutics (6733.TWO) Earnings Analysis
BioGend Therapeutics (6733.TWO) has no confirmed upcoming earnings date. Last quarter (2025-11-06) it beat with EPS -0.05583 TWD vs -0.09 TWD est (+38%). It has beaten estimates in 1/3 recent quarters (33%). Trailing P/E -43.97.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 6733.TWO next report earnings?
No confirmed upcoming earnings date is currently scheduled for 6733.TWO. This page updates as the calendar is published.
6733.TWO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-11-06 | -0.05583 TWD | -0.09 TWD | +38% | Beat |
| 2025-08-07 | -0.19 TWD | -0.18 TWD | -5.6% | Miss |
| 2024-11-08 | -0.25 TWD | -0.18 TWD | -38.9% | Miss |
Beat rate: 1/3 (33%) over reported quarters with consensus data.
6733.TWO valuation and analyst view
| Trailing P/E | -43.97 |
|---|---|
| Trailing EPS | -0.56588 TWD |
| Price / book | 2.71 |
| Dividend yield | 0.00% |
| Market cap | 3.19B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is BioGend Therapeutics (6733.TWO)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 6733.TWO. This page updates as the calendar is published.
Did 6733.TWO beat earnings last quarter?
In its 2025-11-06 report, 6733.TWO posted EPS of -0.05583 TWD versus a -0.09 TWD estimate — a beat of 38%.
What is 6733.TWO's earnings track record?
Over the last 3 reported quarters with consensus data, 6733.TWO beat estimates 1 times (33%).
What is 6733.TWO's current P/E ratio and EPS?
6733.TWO trades at a trailing P/E of -43.97 on trailing EPS of -0.5658779940849556 TWD.
What do analysts rate 6733.TWO?
6733.TWO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.